What Is FGF6? Definition and What Research Reports

Definition

FGF6 (fibroblast growth factor 6) is a secreted signalling protein belonging to the fibroblast growth factor family, a group of related growth factors that bind heparan sulfate and activate cell-surface fibroblast growth factor receptors (FGFRs). It is encoded by the FGF6 gene in humans and is grouped with FGF4 and FGF5 in the FGF4 subfamily on the basis of sequence similarity and receptor preference. Among the FGFs, FGF6 is notable because its expression in adult tissue is comparatively restricted, with skeletal muscle and myogenic precursor cells being the tissue context most often described in the literature. In practical terms, when a paper refers to "FGF6" it is referring either to the gene, to the protein it encodes, or to the recombinant version of that protein used in experiments.

What Class of Molecule Is FGF6?

FGF6 is a protein growth factor, not a short synthetic peptide. That distinction matters for anyone reading peptide literature, because the word "peptide" is often used loosely to cover everything from two-amino-acid fragments to full recombinant proteins. FGFs are single-chain polypeptides with a conserved core beta-trefoil fold; they are produced by cells, secreted or released into the extracellular space, and then engage FGFRs in a complex that typically requires heparan sulfate proteoglycans as a co-factor. Receptor engagement triggers intracellular signalling cascades, including the RAS/MAPK and PI3K/AKT pathways, which are the same downstream routes examined in the tumour studies summarised below.

Where It Comes From

Endogenously, FGF6 is a product of the FGF6 gene and is synthesised by cells of the myogenic lineage; developmental and regeneration biology papers have repeatedly placed it in the skeletal muscle compartment. In a laboratory setting, FGF6 used in experiments is generally recombinant protein expressed in bacterial or mammalian systems and supplied as a research reagent. Recombinant human FGF6 sold for laboratory work carries research-use-only (RUO) labelling in the United States; it is not an approved drug product, and there is no FGF6 medicine approved by the U.S. Food and Drug Administration. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or the interpretation of research findings.

How the Term Is Used in Peptide and Growth-Factor Research

Across the published literature, "FGF6" appears in three broad ways:

• As a gene or transcript. Papers measure FGF6 mRNA expression, copy number or amplification status in tissue samples, often alongside other members of the FGF family.
• As a recombinant protein administered experimentally. Animal studies have delivered FGF6 protein directly into tissue to observe what happens to repair processes.
• As a pathway node. Because FGF6 feeds into FGFR-dependent MAPK and PI3K/AKT signalling, it is frequently discussed in the context of those cascades rather than as a standalone molecule.

It is worth noting what FGF6 is not. It is not one of the short research peptides that circulate under acronym names, it is not a fragment of a larger hormone, and it does not have an established clinical protocol in humans. The literature on FGF6 is preclinical: cell lines, tissue samples, and animal models.

What the Published Literature Reports

Skeletal Muscle Regeneration in Mice

The most frequently cited functional work on FGF6 concerns muscle repair. In a 2003 study in Biochimica et Biophysica Acta, researchers reported that injection of FGF6 accelerated regeneration of the soleus muscle in adult mice, linking the growth factor to the tempo of muscle repair after injury (PMID 12972298). That finding is consistent with the tissue distribution described above: a factor concentrated in the myogenic lineage having a measurable effect when supplied to injured muscle in an animal model. The study was conducted in mice, and its conclusions describe that model rather than a human outcome.

Oral Squamous Cell Carcinoma

More recent work has examined FGF6 in cancer biology, where the direction of effect has not been uniform. A 2024 paper in Scientific Reports reported that FGF6 inhibited oral squamous cell carcinoma progression by regulating the PI3K/AKT and MAPK pathways, positioning FGF6 as a suppressive signal in that particular tumour context (PMID 39506091). The mechanistic framing in that study is the same pair of intracellular cascades that FGFR activation is known to engage, which is why FGF6 papers so often describe results in terms of pathway modulation rather than a single phenotype.

Malignant Meningioma

A separate 2024 report in Translational Oncology examined FGF6 amplification and described it as playing an important role in the progression and treatment of malignant meningioma, an example of FGF6 being studied as a genomic alteration rather than as an administered protein (PMID 38710133). Taken together with the oral carcinoma work, these two papers illustrate a recurring theme in FGF biology: the same growth factor can be associated with opposite-seeming roles depending on tumour type, receptor availability and the surrounding signalling context.

Summary Table of Cited Findings

Safety and Adverse Events: What Studies Report

The verified literature summarised here did not set out to characterise a human safety profile for FGF6, and none of the three cited papers described adverse events in people. The 2003 mouse work reported a regeneration outcome in the soleus muscle rather than a toxicology dataset (PMID 12972298), while the two 2024 oncology papers analysed FGF6 signalling and amplification in tumour contexts rather than administering the protein to humans (PMID 39506091, PMID 38710133). Because growth factors act on proliferative signalling pathways, researchers writing in this space routinely flag tumour biology as a reason for caution in interpreting any growth-factor result, and the meningioma amplification finding is a direct example of why FGF6 copy number is of interest to oncologists (PMID 38710133). No conclusions about human safety can be drawn from the evidence cited on this page.

Terms Readers Often Confuse With FGF6

• FGF2 (basic FGF) — a different, far more widely studied family member with broad tissue expression; findings for FGF2 do not transfer to FGF6.
• FGF21 — a metabolic "endocrine" FGF that signals via klotho co-receptors; a distinct biology from the FGF4 subfamily.
• FGFR1–4 — the receptors FGFs bind, not the ligands themselves. Papers about FGFR inhibitors are about the receptor side of the interaction.
• Myogenic peptides — short synthetic sequences studied in muscle contexts are chemically unrelated to a full recombinant growth factor such as FGF6.

Limitations of the Current Evidence

The FGF6 literature available here is small, preclinical and heterogeneous in design. One animal study addressed muscle repair, and two 2024 papers addressed tumour biology in two unrelated cancers; there is no controlled human trial among them. Findings in a mouse soleus muscle do not establish what would happen in human tissue, and results in one tumour type do not generalise to another. Readers comparing FGF6 to better-characterised growth factors should note that the volume, replication and clinical translation behind FGF6 are substantially thinner. This entry is definitional and descriptive; it does not describe any protocol, regimen or application, and it should not be read as encouragement to use any substance.

References

• FGF6 inhibits oral squamous cell carcinoma progression by regulating PI3K/AKT and MAPK pathways (Scientific Reports, 2024)
• The FGF6 amplification mutation plays an important role in the progression and treatment of malignant meningioma (Translational Oncology, 2024)
• Injection of FGF6 accelerates regeneration of the soleus muscle in adult mice (Biochimica et Biophysica Acta, 2003)